Dolutegravir

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Tivicay · 2.2

• • Always in combination with other antiretrovirals. FDA Tivicay · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Tivicay · 8.1

  “Risk Summary Data from two, ongoing birth outcome surveillance studies in Botswana and Eswatini which together include over 14,000 individuals evaluated during pregnancy show similar prevalence of neural tube defects among infants born to individuals taking dolutegravir at the time of conception compared to those born …”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Tivicay · 8.2

  “Risk Summary Dolutegravir is present in human milk.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Tivicay · 8.4

  “Children and Adolescent Participants with HIV 1 The safety, pharmacokinetics, and effectiveness of TIVICAY and TIVICAY PD were evaluated in 75 treatment-naïve or treatment-experienced, INSTI-naïve pediatric and adolescent participants with HIV‑1 aged 4 weeks to less than 18 years weighing at least 3 kg in an …”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Tivicay · 8.5

  “In general, caution should be exercised in the administration of TIVICAY in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see Clinical Pharmacology ( 12.3 )] .”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.